BREAKING NEWS

President Trump holds White House meeting
Bandage-strip–sized patch could transform immunizations
Budget analysts again see millions of Americans going without insurance
Reform supplements the GOP’s American Health Care Act
An estimated 9% of charges are initially denied
Agency takes steps under new Drug Competition Action Plan

P&T TV

SIRT for Liver Cancer: Similar Efficacy, Less Toxicity Than Sorafenib

Valérie Vilgrain, MD, of Hôpital Beaujon Service de Radiologie in Paris, describes results of the SARAH trial. Selective internal radiation therapy provided efficacy similar to sorafenib for hepatocellular carcinoma but with considerably fewer adverse events.

European Association for the Study of the Liver International Liver Congress, April 2017

P&T June 2017
Table of Contents

Features

This article, the first in a series of three, introduces cancer immunology, cancer immunotherapy strategies, and the classes of anticancer therapeutic agents.
Newer atypical antipsychotics have favorable safety and efficacy profiles, but their use is often limited by high cost. The authors present one institution’s antipsychotic tablet-splitting program that resulted in substantial savings.
The rising cost of cancer treatments has prompted institutions to employ cost-saving, reimbursement-maximizing strategies. After implementing a policy governing inpatient administration of antineoplastic medications, one community teaching hospital successfully decreased the associated drug costs.
Pipeline Plus
We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.
Meeting Highlights
The latest in hepatology research was presented at this year’s European Association for the Study of the Liver (EASL) International Liver Congress.
Meeting Highlights
Highlights of the AMCP Annual Meeting included marketplace trends, the affordability crisis, and the issues facing value-based contracting.

Departments

Medication Errors
Unverified patient-reported errors can have real consequences
Prescription: Washington
Drug companies breathe easier as PDUFA VI heads for approval
Approvals, new indications, regulatory activities, and more
Ribociclib (Kisqali) for HR+/HER2− advanced or metastatic breast cancer in postmenopausal women; safinamide (Xadago) as adjunctive treatment for patients with Parkinson’s disease; and avelumab (Bavencio) for metastatic Merkel cell carcinoma
Drug Forecast
Pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with Parkinson’s disease